<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04861948</url>
  </required_header>
  <id_info>
    <org_study_id>CIBI188A104</org_study_id>
    <nct_id>NCT04861948</nct_id>
  </id_info>
  <brief_title>IBI188 Combination Therapy in Solid Tumors</brief_title>
  <official_title>Phase Ib Study to Evaluate the Efficacy, Safety and Tolerability of IBI188 Combination Therapy in Subjects With Advanced Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Innovent Biologics (Suzhou) Co. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Innovent Biologics (Suzhou) Co. Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase Ib study aim to explore the efficacy, safety, and tolerability of IBI188 combination&#xD;
      therapy in subjects with advanced malignancies&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 25, 2021</start_date>
  <completion_date type="Anticipated">October 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>24 months</time_frame>
    <description>Incidence, correlation with the study drug and severity of all adverse events (AEs), treatment-emergent adverse events (TEAEs), adverse events of special interest (AESIs) and serious adverse events (SAEs)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to response</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under Curve, AUC</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>maximum concentration (Cmax)</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>minimum concentration (Cmin)</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>clearance (CL)</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>volume of distribution (V)</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>half-life (t1/2)</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Positive rate of anti-drug antibody (ADA)</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Positive rate of neutralizing antibody (NAb)</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Solid Tumors</condition>
  <condition>Lung Adenocarcinoma</condition>
  <condition>Osteosarcoma</condition>
  <arm_group>
    <arm_group_label>Cohort A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IBI188</intervention_name>
    <description>intravenous</description>
    <arm_group_label>Cohort A</arm_group_label>
    <arm_group_label>Cohort B</arm_group_label>
    <arm_group_label>Cohort C</arm_group_label>
    <arm_group_label>Cohort D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GM-CSF</intervention_name>
    <description>subcutaneous injection</description>
    <arm_group_label>Cohort C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin/Carboplatin</intervention_name>
    <description>intravenous</description>
    <arm_group_label>Cohort B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>intravenous</description>
    <arm_group_label>Cohort B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sintilimab</intervention_name>
    <description>intravenous</description>
    <arm_group_label>Cohort A</arm_group_label>
    <arm_group_label>Cohort D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pemetrexed</intervention_name>
    <description>intravenous</description>
    <arm_group_label>Cohort B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with locally advanced or metastatic solid tumors cannot be cured by surgery&#xD;
             or other local treatments .&#xD;
&#xD;
          2. Aged ≥ 18 years (≥ 12 years is acceptable in Cohort C).&#xD;
&#xD;
          3. Able to provide archived or fresh tumor tissue samples for biomarker assessment.&#xD;
&#xD;
          4. Have at least one measurable lesion according to RECIST version 1.1.&#xD;
&#xD;
          5. ECCG PS score of 0-2.&#xD;
&#xD;
          6. Adequate organ and bone marrow functions .&#xD;
&#xD;
          7. Life expectancy ≥ 12 weeks.&#xD;
&#xD;
          8. Female subjects of childbearing potential or male subjects with partners of&#xD;
             childbearing potential should take effective contraceptive measures throughout the&#xD;
             whole treatment period and until 6 months after treatment.&#xD;
&#xD;
          9. Must voluntarily sign the Informed Consent Form (ICF), and be able to follow all study&#xD;
             requirements and procedures. For the subjects enrolled in Cohort C who are ≥ 12 and &lt;&#xD;
             18 years old, in addition to obtaining the child's own consent, their guardians should&#xD;
             provide informed consent and sign the ICF.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Previous exposure to any CD47 antibody, SIRPα antibody, CD47/SIRPα recombinant protein&#xD;
             or other inhibitors that act in the same pathway.&#xD;
&#xD;
          2. Previous exposure to any anti-programmed death receptor 1 (PD-1) or anti-programmed&#xD;
             death-ligand (PD-L1) antibody (except Cohort C).&#xD;
&#xD;
          3. Concurrent participation in another clinical study.&#xD;
&#xD;
          4. The last dose of anti-tumor therapy is within 4 weeks before the first dose of study&#xD;
             treatment.&#xD;
&#xD;
          5. Have undergone major surgical procedures within 4 weeks prior to the first dose of&#xD;
             study treatment or planned to receive major surgery during the study treatment.&#xD;
&#xD;
          6. Presence of toxicities (excluding alopecia and fatigue) induced by previous anti-tumor&#xD;
             therapy that has not recovered to Grade 0 or 1 as assessed by National Cancer&#xD;
             Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v5.0 prior to&#xD;
             the first dose of study treatment.&#xD;
&#xD;
          7. Known hypersensitivity to IBI188 or any ingredient in the study drug product.&#xD;
&#xD;
          8. History of other primary malignancies.&#xD;
&#xD;
          9. Female subjects who are pregnant or lactating.&#xD;
&#xD;
         10. Other ineligible conditions considered by the investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ba Yi</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tianjin Medical University Cancer Institute and Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Zhang Dahong</last_name>
    <role>Principal Investigator</role>
    <affiliation>Zhejiang Provincial People's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Guo Hongqian</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Fang Meiyu</last_name>
    <role>Principal Investigator</role>
    <affiliation>Zhejiang Cancer Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Xie Yu</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hunan Cancer Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Liu Jisheng</last_name>
    <role>Principal Investigator</role>
    <affiliation>First Affiliated Hospital of Soochow University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Wang Ying</last_name>
    <role>Principal Investigator</role>
    <affiliation>Zhejiang Provincial People's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Wang Haiying</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shougang Hospital, Peking University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Wang Mengzhao</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shougang Hospital, Peking University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lv Qiang</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jiangsu Provincial People's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Li Xiangping</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nanfang Hospital of Southern Medical University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Liu Guihong</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Affiliated Hospital of Xuzhou Medical University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mou Weiqi</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chongqing University Cancer Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Guo Wei</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking Union Medical College</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Wang Wei</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hunan Cancer Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Xu Chongyuan</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nanfang Hospital of Southern Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wang Hongping</last_name>
    <phone>13436623301</phone>
    <email>hongping.wang@innoventbio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Tianjin Medical University Cancer Institute and Hospital</name>
      <address>
        <city>Tianjin</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ba Yi</last_name>
      <phone>86-022-23340123</phone>
      <email>bayi@tjmch.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>April 22, 2021</study_first_submitted>
  <study_first_submitted_qc>April 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 27, 2021</study_first_posted>
  <last_update_submitted>July 18, 2021</last_update_submitted>
  <last_update_submitted_qc>July 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteosarcoma</mesh_term>
    <mesh_term>Adenocarcinoma of Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

